# LOTIS-9 (loncastuximab tesirine): what clinicians are saying

> 49 statements from 13 sources (1 podcast, 3 videos, 6 posts, 1 paper, 2 registry records), 11 of them from 2 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026.

## Report

- Trial: A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
- NCT ID: NCT05144009
- Registry: https://clinicaltrials.gov/study/NCT05144009
- Sponsor: ADC Therapeutics S.A.
- Phase: Phase 2
- Status: Terminated
- Drugs tested: loncastuximab tesirine plus rituximab
- Indication: previously untreated unfit/frail diffuse large B-cell lymphoma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-22 UTC
- Last checked: 2026-11-22 UTC
- Release hash: a30a17c1d1b2c26501bb9a17adf1c8843a249bc383edd244bca6559d62f2f382

## Counts

- Commentary sources screened: 46
- Sources cited by verified statements: 13
- Verified statements: 49
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 11
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 7
- Speakers cited: 7
- Cited speakers with a verified identity: 6
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 2
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 2
- By role and specialty (the abstract's specialty counts):
  - 1 physician, specialty not confirmed
  - 1 physician, Medical oncology
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

One speaker reads LOTIS-9 as a warning that avoiding chemotherapy does not remove toxicity, citing pulmonary deaths while questioning their reported attribution to comorbidities rather than drug effects. Their concern turns on cardiopulmonary reserve that functional frailty scores may not capture. Their comparison with R-mini-CHOP acknowledges different populations, leaving relative benefit unresolved. Another speaker calls for frailty-specific trials powered to assess benefit and toxicity; the discussion does not establish that treatment caused the deaths.

## Question clinicians left open

What do clinicians say would clarify whether pulmonary deaths in LOTIS-9 reflected comorbidities alone or also toxicity from loncastuximab tesirine plus rituximab as chemotherapy replacement in previously untreated unfit or frail DLBCL?

From findings F1 (11 statements from 2 speakers in 5 sources) and F4 (10 statements from 2 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. LOTIS-9: speakers question AE attribution; one relays trial-only advice
  - 11 statements from 2 speakers in 5 sources.
  - 2 of the 2 named speakers in this finding hold this view; 1 of them holds its caveat, “one relays trial-only advice”.
  - No named clinician · accounts and unnamed speakers.
- F2. Frailty and chemo-free care: why a speaker still stresses supportive care
  - 3 statements from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F3. LOTIS-9 CRs: a speaker questions value vs R-mini-CHOP despite differing populations
  - 6 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F4. LOTIS-9: speakers welcome testing; a clinician ties an RCT to durable responses
  - 10 statements from 2 speakers in 4 sources, 3 of them podcasts or videos.
  - 2 of the 2 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician ties an RCT to durable responses”.
  - 1 of the report's 2 cited clinicians.
- F5. Older/unfit frontline DLBCL: a speaker highlights activity, not proof of superiority
  - 6 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view; 1 of them holds its caveat, “not proof of superiority”.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F6. Loncastuximab Tesirine: what speakers say
  - 5 statements from 3 speakers in 2 sources.
  - 1 of the report's 2 cited clinicians.
- F7. Frailty trials: why a speaker seeks power for both efficacy and toxicity
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F8. Contemporary combinations: why a speaker sees possible future standards
  - 1 statement in 1 source, a podcast or video.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.

3 of the 8 findings and 6 of the 49 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 11 | 5 | 5 | 2 | 3 |
| F2 | 3 | 1 | 1 | 1 | 2 |
| F3 | 6 | 2 | 2 | 1 | 3 |
| F4 | 10 | 4 | 4 | 2 | 3 |
| F5 | 6 | 2 | 2 | 1 | 3 |
| F6 | 5 | 4 | 2 | 3 | 3 |
| F7 | 1 | 1 | 1 | 1 | 2 |
| F8 | 1 | 2 | 1 | 0 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 4 | 0 | 0 | 0 | 7 | 11 | 0 | 4 posts and articles, 1 publication |
| F2 | 3 | 0 | 0 | 0 | 0 | 3 | 0 | 1 post or article |
| F3 | 1 | 0 | 0 | 1 | 4 | 6 | 0 | 1 post or article, 1 publication |
| F4 | 5 | 2 | 0 | 1 | 2 | 10 | 0 | 1 post or article, 3 podcasts and video |
| F5 | 3 | 0 | 0 | 1 | 2 | 7 | 0 | 1 post or article, 1 publication |
| F6 | 3 | 0 | 2 | 0 | 0 | 5 | 2 | 2 posts and articles |
| F7 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 post or article |
| F8 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: CR Rate: F1 (1 shared claims), F3 (2 shared claims), F5 (1 shared claims)
- Primary endpoint: Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment: F3 (1 shared claims)
- Secondary endpoints: F1 (4 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (2 shared claims)
- Population and setting: F1 (3 shared claims), F2 (2 shared claims), F4 (8 shared claims), F5 (1 shared claims)
- The comparison: F3 (1 shared claims), F4 (4 shared claims), F5 (3 shared claims)
- Safety and tolerability: F1 (8 shared claims), F2 (3 shared claims), F3 (2 shared claims), F5 (2 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (3 shared claims)

## Abbreviations

- AE: adverse event
- CR: complete response
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- RCT: randomized controlled trial

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 49 | Paid |
| Who said each statement: the cited speakers | 7 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 2 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 6 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 13 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 2 of the 7 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: CR Rate | discussed | 4 | 3 |
| Primary endpoint: Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment | discussed | 1 | 1 |
| Secondary endpoints | discussed | 7 | 5 |
| Population and setting | discussed | 15 | 7 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 8 | 5 |
| Safety and tolerability | discussed | 14 | 5 |
| Design and conduct | discussed | 9 | 5 |
| Off-trial boundaries and transparent reporting | discussed | 3 | 2 |
| Organ reserve and supportive-care requirements | discussed | 3 | 1 |
| Treatment burden and patient-centered selection across alternatives | discussed | 5 | 1 |
| Broader drug adoption and accelerated-approval confidence | discussed | 4 | 2 |
| Long-term expectations for contemporary combinations | discussed | 1 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 10 statements · 20%** | | | |
| YouTube | 9 | 3 | 3 |
| Podcasts | 1 | 1 | 1 |
| **Posts · 26 statements · 53%** | | | |
| X threads | 15 | 5 | 41 |
| LinkedIn posts | 11 | 1 | 1 |
| **Primary sources · 13 statements · 27%** (cited for context, not screened) | | | |
| Registry (primary source, cited for context) | 9 | 2 | not screened |
| Publications (primary source, cited for context) | 4 | 1 | not screened |

- Screened window: 2022-07-06 to 2026-10-28
- Cited window: 2022-07-06 to 2026-10-28
- Retrieved: 2026-11-22

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
- Registry: NCT05144009 (https://clinicaltrials.gov/study/NCT05144009)
- Study IDs: ADCT-402-203 · 2021-005312-57 · 2022-501601-12-00
- Sponsor: ADC Therapeutics S.A.
- Design: Phase 2 · interventional, non randomized, sequential, phase2
- Status: Terminated
- Enrollment: 41 (actual)
- Start: 2022-06-21 (actual)
- Primary completion: 2024-01-22 (actual)
- Primary endpoint: CR Rate (Up to a maximum of 17.1 months)
- Primary endpoint: Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment (Up to 12 weeks (3 week cycle length))
- Intervention: Loncastuximab Tesirine (drug)
- Intervention: Rituximab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a remark on trial discontinuation in previously untreated unfit or frail diffuse large B-cell lymphoma; a view on frontline polatuzumab-containing treatment, its approval basis, comparative efficacy, and follow-up limitations; a view on pretreatment assessment, treatment urgency and systemic versus local therapy in newly diagnosed diffuse large B-cell lymphoma.
- 3 passages in 1 source used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 39 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 10 sources about other trials or topics are not included.
- The sources reviewed for this edition are a selective set of public discussions, not a representative sample of HCP opinion. Multiple sources or posts must not be interpreted as multiple independent clinicians.
- Discussion that did not name LOTIS-9 or used different wording may be missing. Some relevant podcast passages, including discussion of a frontline polatuzumab-containing regimen, were not fully assessed.
- Not all podcast statements can be assigned to named participants. The long-term treatment-landscape expectation therefore remains attributed to the episode rather than to a named speaker.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The July 2023 safety-hold discussion, 2022 rationale interviews and 2026 commentary describe different moments. Dates alone do not establish a change of mind or direct disagreement.
- ClinicalTrials.gov first posted results for the trial on 30 January 2025. The cited commentary spans 2022–2026 rather than wholly predating that posting.
- Cross-trial benchmarks and the shared-slide treatment snapshot do not establish comparative efficacy. The discrepant LOTIS-9 figures in the slide account and publication are not explained by the sources.
- Reported adverse events and clinical anecdotes do not establish treatment causality. The prophylaxis pattern does not establish prevention of fatal events, and the brief clinic reply does not identify an adverse-event type or patient population.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-22 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-22 UTC. No changes.

## Offer

- Size: Focused · 49 verified statements · 11 from 2 confirmed clinicians
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/lotis-9-nct05144009/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=lotis-9-nct05144009

## Cite

Erudio Health. LOTIS-9 (NCT05144009): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/lotis-9-nct05144009

## Questions

### How much does the LOTIS-9 report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the LOTIS-9 report cover?

49 statements from 13 sources (1 podcast, 3 videos, 6 posts, 1 paper, 2 registry records), 11 of them from 2 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the LOTIS-9 report?

Its preview, yes: get_report_card({ "slug": "lotis-9-nct05144009" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the LOTIS-9 report?

Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/lotis-9-nct05144009.json
- Markdown: https://www.erudio.com/reports/lotis-9-nct05144009.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/lotis-9-nct05144009/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "lotis-9-nct05144009"}`
